Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Shares Down 2.1%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVFGet Rating)’s share price dropped 2.1% during trading on Tuesday . The stock traded as low as $22.33 and last traded at $22.43. Approximately 200 shares traded hands during trading, a decline of 78% from the average daily volume of 923 shares. The stock had previously closed at $22.91.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Nordea Equity Research upgraded shares of Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “buy” rating in a report on Friday, April 14th. Royal Bank of Canada raised shares of Swedish Orphan Biovitrum AB (publ) from a “sector perform” rating to an “outperform” rating in a research note on Thursday, April 13th.

Swedish Orphan Biovitrum AB (publ) Trading Down 2.1 %

The stock has a 50-day moving average of $23.78 and a two-hundred day moving average of $22.33. The company has a market cap of $6.62 billion, a P/E ratio of 22.43 and a beta of 0.49. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.53 and a current ratio of 0.75.

About Swedish Orphan Biovitrum AB (publ)

(Get Rating)

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases.

Further Reading

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.